Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3D128
- Development stage
- Preclinical
- Lead developer
- 3D Medicines
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
3D128 is a preclinical *in vivo* chimeric antigen receptor (CAR) T-cell therapy candidate developed by 3D Medicines for the treatment of hematologic malignancies. Unlike conventional *ex vivo* CAR-T therapies that require complex laboratory processing of patient cells, 3D128 utilizes an *in vivo* approach to genetically engineer T cells directly within the patient's body to express CARs targeting tumor antigens. This technology aims to overcome the logistical and manufacturing challenges associated with traditional cell therapies, potentially providing a more accessible and rapid treatment option for patients with blood cancers.
Beyond the preview
Go deeper on 3D128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3D128.